Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare® oncology information system (OIS) which is currently in development at RaySearch. Under the contract, Accuray will have the opportunity to offer RayCare® in several designated major radiation therapy markets, making available a fully-integrated solution with the TomoTherapy® and CyberKnife® System product portfolios. RaySearch, known for its innovative, advanced and user-friendly treatment planning software, RayStation®, and Accuray, recognized for its innovative tumor treatments, are partnering to provide the radiation oncology community with a creative approach for delivering and managing precise radiation therapy.
RayCare® is a next generation OIS developed from the ground up by RaySearch to support the complex logistical challenges in modern large-scale radiation therapy centers. RayCare® integrates the high performance radiation therapy algorithms available in RayStation® and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. The system is expected to be released in 2017.
"In today's complex healthcare environment it is becoming increasingly important to deliver clinical excellence and successful outcomes for cancer patients through radiation treatment options, which are both effective and efficient," said Joshua H. Levine, president and chief executive officer of Accuray. "Our goal in partnering with RaySearch is to provide solutions that will enhance the integration of the TomoTherapy and CyberKnife technologies with our customers' oncology department workflow, enabling them to more easily manage the large volumes of clinical data and to streamline their patients' radiation treatments."
"The RaySearch and Accuray collaboration agreement brings together two companies dedicated to providing clinicians with innovative solutions which result in more effective radiation therapy for cancer patients," said Johan Lof, president and chief executive officer of RaySearch Laboratories AB (publ). "We believe RayCare® has the potential to set a new standard for oncology information systems and will enable cancer centers to optimize their workflow and use of resources to maximize the level of care they provide to their patients."
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare